T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies
Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.
Los Angeles, USA, May 05, 2021 (GLOBE NEWSWIRE) -- *T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies *
Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.
DelveInsight’s *‘**T-cell Leukemia Pipeline Insights**’* report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the T-cell Leukemia domain.
Some of the key highlights of the *T-cell Leukemia Pipeline* report:
· T-cell Leukemia Pipeline report offers a comprehensive analysis of* 15+ *key players and *15+* key therapies.
· Out of all the emerging therapies, *HBI-8000* is expected to capture the maximum patient pool owing to its immunomodulatory function. This oral agent targets class I histone deacetylase causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma.
· T-cell Leukemia pipeline comprises *ASTX 660* (Otsuka Pharmaceutical) is in phase I/II while Valemetostat and Brentuximab vedotin (Seagen/Takeda) is in Phase II stage of development.
· *HUYA Bioscience* appears to have an upper edge as its therapy, HBI-8000 which is in the pre-registration phase.
· In April 2021, *Shorla Pharma* announced that the U.S. Food and Drug Administration (FDA) has accepted the filing application of its oncology drug* SH-111 *which is designed to treat T-cell Leukemia.
Got queries? Want to know more? Request for Sample @ *T-cell Leukemia Emerging Therapies and Forecast *
The report lays down a complete coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for T-cell Leukemia across the complete product development cycle, including all clinical and non-clinical stages.
The T-cell Leukemia pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs.
*T-cell Leukemia Pipeline Drugs *
*Drug* *Company* *Clinical Phase* *MoA* *RoA*
*Valemetostat* Daiichi Sankyo Phase II Histone-lysine N-methyltransferase inhibitors Oral
*BNZ-1* Bioniz Phase II Interleukin receptor antagonists Intravenous
*ASTX 660* Otsuka Pharmaceutical Phase I/II Inhibitor of apoptosis protein inhibitors; Oral
*Brentuximab vedotin* Seagen /
Takeda Phase II Apoptosis stimulants Intravenous
*HBI-8000* HUYA Bioscience Preregistration Ras protein inhibitors Oral
Request for Sample to know more @ *T-cell Leukemia Pipeline Analysis, Key Companies and Futuristic Trends *
*T-cell Leukemia Therapeutic Assessment *
The T-cell Leukemia Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
*By Product Type*
· Mono
· Combination
*By Stage*
· Discovery
· Pre-clinical
· IND
· Phase I
· Phase II
· Phase III
· Pre-registration
*By Molecule Type*
· Small Molecule
· Gene Therapy
· Stem Cell Therapy
*By Route of Administration*
· Intravenous
· Inhalation
· Oral
· Subcutaneous
*By Mechanism of Action*
· Enhancer of zeste homolog 1 and 2 protein inhibitors
· Histone-lysine N-methyltransferase inhibitors
· Interleukin 15 receptor antagonists
· Interleukin 2 receptor antagonists
· Interleukin 9 receptor antagonists
· 1 Phosphatidylinositol 3 kinase inhibitors
· HDAC 1,2,3, and 10 protein inhibitors
· Mitogen-activated protein kinase inhibitors
*By Targets*
· Protease
· Multiple Kinase
· Interleukin 15 receptor
· Interleukin 2 receptor
· Interleukin 9 receptor
· Histone-lysine N-methyltransferase
Get in touch with our Business executive for* Rich and Deep Market Assessment and Consulting Solutions *
*Scope of the Report*
*Coverage*: Global
*Key Players*: Daiichi Sankyo; Bioniz; Otsuka Pharmaceutical; Seagen /Takeda; HUYA Bioscience; iCell Gene Therapeutics; Gracell Biotechnology; Ascentage Pharma Group; Celgene Corporation; Shorla Pharma; AVM Biotechnology; Expression Therapeutics; miRagen Therapeutics, and others.
*Key T-cell Leukemia Pipeline Therapies*: Valemetostat; BNZ-1; ASTX 660; Brentuximab vedotin; HBI-8000; CD4CAR; CD7 UCAR-T cells; APG-115; Romidepsin; SH-111; Cobomarsen; AVM-0703, and others.
Reach out @ *T-cell Leukemia Pipeline: Novel therapies and emerging technologies*
*Table of Contents *
1 Introduction
2 Executive Summary
3 T-cell Leukemia Overview
4 T-cell Leukemia Pipeline Therapeutics
5 T-cell Leukemia Pipeline Therapeutic Assessment
6 T-cell Leukemia – DelveInsight’s Analytical Perspective
7 In-depth Commercial T-cell Leukemia Pipeline Assessment
8 T-cell Leukemia Collaboration Deals
9 Late Stage T-cell Leukemia Pipeline Products (Phase III and Preregistration)
10 Mid-Stage T-cell Leukemia Pipeline Products (Phase II)
11 Pre-clinical and Discovery Stage T-cell Leukemia Pipeline Products
12 Inactive T-cell Leukemia Pipeline Products
13 T-cell Leukemia Key Companies
14 T-cell Leukemia Key Products
15 T-cell Leukemia Unmet Needs
16 T-cell Leukemia Market Drivers and Barriers
17 T-cell Leukemia Future Perspectives and Conclusion
18 T-cell Leukemia Pipeline Analyst Views
20 Appendix
Visit to know more of what’s covered @ *T-cell Leukemia Emerging Therapies*
*Browse through Related Reports*
*CAR T-Cell Therapy for Acute Lymphoblastic Leukemia*
DelveInsight’s “*CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030*” report.
*CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline *
DelveInsight’s, “*CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,*” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape.
*Adult T Cell Leukemia Lymphoma Market*
DelveInsight's "*Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030*" report.
*Acute Myeloid Leukemia Market*
DelveInsight's "*Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030*" report.
*B-Cell Chronic Lymphocytic Leukemia Market*
DelveInsight's "*B-Cell Chronic Lymphocytic Leukemia - Market Insights, Epidemiology, and Market Forecast-2030*" report.
*Hairy Cell Leukemia Market Insight Epidemiology and Market Forecast*
DelveInsight's '*Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028*' report.
*Bowens Disease Market*
DelveInsight's "*Bowen's Disease - Market Insights, Epidemiology, and Market Forecast-2030*" report.
*Buergers Disease Market*
DelveInsight's "*Buerger’s Disease - Market Insights, Epidemiology, and Market Forecast-2030*" report.
*Brucellosis Market*
DelveInsight's "*Brucellosis - Market Insights, Epidemiology, and Market Forecast-2030*" report.
*About **DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform *PharmDelve*.
For more insights, visit *Pharma, Healthcare, and Biotech News *
CONTACT: Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com